Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
Arnon Cohen, MD, MPH, PhD
Clalit Health Services
Tel Aviv, Israel
IPC Councilor
PUBLICATION
COMMENTARY
In a study published in The Lancet Rheumatology, a research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity against SARS-CoV-2 spike glycoprotein in sixty-seven patients with psoriasis as compared to fifteen healthy controls after the second dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech). Patients included in the study received methotrexate (n=14), TNF inhibitors (n=19), IL-17 inhibitors (n=14), or IL-23 inhibitors (n=20). The median age was 44 years, with 52% males and 87% of White ethnicity. The study demonstrated that functional humoral immunity was not impaired by methotrexate or biologics, as observed that after the second dose of vaccine, as both patients and controls had neutralizing antibodies against wild-type SARS-CoV-2 and two variants. However, 38% of 13 participants on methotrexate and 26% of 50 participants on targeted biologics did not have detectable T-cell responses following the second dose of vaccine. There was no difference in the magnitude of T-cell responses between patients receiving methotrexate (median cytokine-secreting cells per 10⁶ cells 160, targeted biologics (169), and controls (185).
The observations on antibody development after COVID-19 vaccination in patients treated with methotrexate or targeted immunosuppressive agents are reassuring. However, the observation of absence of boosting of T-cell responses might indicate that durable cellular and humoral immunity may be impaired in some of the patients receiving these drugs.
Implications
Limitations
Limitations of the study are that patients with psoriasis not receiving immunosuppressants were not included, and that most participants were of White ethnicity. As the number of patients included and study and the duration of follow-up are limited, it is possible that differences may become statistically significant with a larger sample size or with longer follow-up.
Categories
Recent Posts
Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis
Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research
Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD
Also Read
Focus on Psoriasis: A Report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV)
Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This report covers significant updates on psoriasis, including the International Psoriasis Council’s Symposium and late-breaking sessions. Download the full EADV Congress Report for a comprehensive overview of psoriasis presentation and treatment advancements.
Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares
Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.
Medical Adherence for Orals Systemics, Biologics, and Phototherapy in the Context of Psoriasis Patients
Learn the dynamics of psoriasis treatments, emphasizing patient adherence challenges. From evolving therapies to oral and biologic agents, understand real-world data and adherence patterns. Gain insights into long-term disease management and the crucial role of adherence in optimizing patient outcomes.
Subscribe to the IPC Newsletter